<DOC>
	<DOC>NCT02461719</DOC>
	<brief_summary>The purpose of this clinical Study is TJCS Eye Drops 0.05%(Cyclosporine ophthalmic nano-emulsion) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12 weeks after treatment, each treatment group comparisons for evaluation of efficacy and safety in Moderate to Severe Dry Eye Disease.</brief_summary>
	<brief_title>Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Male or female, age 20 or over Patients with moderate to severe dry eye Screening both eyes, the corrected visual acuity is 0.2 or more Screening visits within 4 weeks who treated with systemic cyclosporine or topical cyclosporine ophthalmic solutions. Screening visits within 2 months the patients with systemic or ocular disorders affected the test results (ocular surgery, trauma, or disease) Intraocular pressure(IOP)&gt; 25 mmHg Patient using or to use punctual plug within 1 months. Patients with contact lens.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>